These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18533605)

  • 1. [Treatment of type 2 diabetes with new oral antihyperglycaemic drugs].
    Seissler J
    MMW Fortschr Med; 2008 May; 150(18):27-31. PubMed ID: 18533605
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapeutic use and adverse events of incretin-related drugs].
    Ishikawa M; Yamada Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
    [No Abstract]   [Full Text] [Related]  

  • 3. Alogliptin (nesina) for type 2 diabetes.
    Med Lett Drugs Ther; 2013 May; 55(1417):41-3. PubMed ID: 23715128
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
    Wang Y; Zhao L; Huang Q; Peng Y
    J Diabetes; 2014 Mar; 6(2):164-6. PubMed ID: 23879890
    [No Abstract]   [Full Text] [Related]  

  • 5. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF
    Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating incretin-based therapy into type 2 diabetes management.
    Brunton SA
    J Fam Pract; 2013 Jun; 62(6 Suppl CME):S1-8. PubMed ID: 23828807
    [No Abstract]   [Full Text] [Related]  

  • 7. Exenatide (Byetta) for type 2 diabetes.
    Med Lett Drugs Ther; 2005 Jun; 47(1210):45-6. PubMed ID: 15933616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes under control: Understanding oral antidiabetic agents.
    Longo R
    Am J Nurs; 2010 Feb; 110(2):49-52. PubMed ID: 20107402
    [No Abstract]   [Full Text] [Related]  

  • 9. [Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].
    Kern W
    MMW Fortschr Med; 2010 Jan; 151 Suppl 4():173-8. PubMed ID: 21595145
    [No Abstract]   [Full Text] [Related]  

  • 10. [New drugs in type 2 diabetes mellitus therapy].
    Kvapil M
    Vnitr Lek; 2013 Aug; 59(8):713-8. PubMed ID: 24007229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canagliflozin, alogliptin benzoate, and ospemifene.
    Hussar DA; Frimpong JO
    J Am Pharm Assoc (2003); 2013; 53(4):442-7. PubMed ID: 23892821
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
    Grunberger G
    J Diabetes; 2013 Sep; 5(3):241-53. PubMed ID: 23489968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
    Xu L; Spinas GA; Niessen M
    Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
    [No Abstract]   [Full Text] [Related]  

  • 14. Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance.
    Adler AI; Shaw EJ; Stokes T; Ruiz F;
    BMJ; 2009 May; 338():b1668. PubMed ID: 19465464
    [No Abstract]   [Full Text] [Related]  

  • 15. Three new drugs for type 2 diabetes.
    Drug Ther Bull; 2008 Jul; 46(7):49-52. PubMed ID: 18603639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic].
    Ahrén B
    Lakartidningen; 2007 Dec; 104(49-50):3763-4. PubMed ID: 18214322
    [No Abstract]   [Full Text] [Related]  

  • 18. Distinguishing among incretin-based therapies. Introduction.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 analogues for type 2 diabetes.
    Wilding JP; Hardy K
    BMJ; 2011 Feb; 342():d410. PubMed ID: 21325387
    [No Abstract]   [Full Text] [Related]  

  • 20. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.